- QUARTERLY RESULTS
Aurobindo Pharma Ltd.
Represents Equity.Intra - day transactions are permissible and normal trading is done in this category
BSE Live
Jan 17, 16:00
486.25
10.10 (2.12%)
Volume
90,692
AVERAGE VOLUME
5-Day
98,023
10-Day
90,754
30-Day
95,930
-
Prev. Close
476.15
-
Open Price
476.30
-
Bid Price (Qty.)
0.00 (0)
-
Offer Price (Qty.)
0.00 (0)
NSE Live
Jan 17, 15:59
485.95
10.10 (2.12%)
Volume
2,644,076
AVERAGE VOLUME
5-Day
2,728,268
10-Day
2,331,297
30-Day
2,519,707
-
Prev. Close
475.85
-
Open Price
477.40
-
Bid Price (Qty.)
485.95 (53)
-
Offer Price (Qty.)
0.00 (0)
Financials
| Quarterly Results of Aurobindo Pharma (in Rs. Cr.) | Sep '19 | Jun '19 | Mar '19 | Dec '18 | Sep '18 | |
| Net Sales/Income from operations | 3,145.12 | 2,997.03 | 3,196.20 | 3,160.50 | 3,090.38 | |
| Other Operating Income | 76.54 | 81.80 | 84.38 | 87.60 | 80.01 | |
| Total Income From Operations | 3,221.66 | 3,078.83 | 3,280.58 | 3,248.10 | 3,170.39 | |
| EXPENDITURE | ||||||
| Consumption of Raw Materials | 1,586.16 | 1,615.40 | 1,708.20 | 1,704.14 | 1,608.99 | |
| Purchase of Traded Goods | 1.34 | 2.38 | 0.58 | 3.71 | 7.43 | |
| Increase/Decrease in Stocks | 38.01 | -75.72 | -136.90 | -22.43 | -11.34 | |
| Power & Fuel | -- | -- | -- | -- | -- | |
| Employees Cost | 374.06 | 377.56 | 361.82 | 349.86 | 331.80 | |
| depreciat | 117.93 | 115.15 | 109.33 | 109.10 | 100.94 | |
| Excise Duty | -- | -- | -- | -- | -- | |
| Admin. And Selling Expenses | -- | -- | -- | -- | -- | |
| R & D Expenses | -- | -- | -- | -- | -- | |
| Provisions And Contingencies | -- | -- | -- | -- | -- | |
| Exp. Capitalised | -- | -- | -- | -- | -- | |
| Other Expenses | 590.88 | 608.80 | 612.54 | 614.50 | 626.54 | |
| P/L Before Other Inc. , Int., Excpt. Items & Tax | 513.28 | 435.26 | 625.01 | 489.22 | 506.03 | |
| Other Income | 33.64 | 30.14 | 28.31 | 136.87 | 4.18 | |
| P/L Before Int., Excpt. Items & Tax | 546.92 | 465.40 | 653.32 | 626.09 | 510.21 | |
| Interest | 24.86 | 31.95 | 34.84 | 41.41 | 30.80 | |
| P/L Before Exceptional Items & Tax | 522.06 | 433.45 | 618.48 | 584.68 | 479.41 | |
| Exceptional Items | -- | -- | -- | -- | -- | |
| P/L Before Tax | 522.06 | 433.45 | 618.48 | 584.68 | 479.41 | |
| Tax | 123.93 | 102.95 | 158.34 | 121.17 | 98.46 | |
| P/L After Tax from Ordinary Activities | 398.13 | 330.50 | 460.14 | 463.51 | 380.95 | |
| Prior Year Adjustments | -- | -- | -- | -- | -- | |
| Extra Ordinary Items | -- | -- | -- | -- | -- | |
| Net Profit/(Loss) For the Period | 398.13 | 330.50 | 460.14 | 463.51 | 380.95 | |
| Equity Share Capital | 58.59 | 58.59 | 58.59 | 58.59 | 58.59 | |
| Reserves Excluding Revaluation Reserves | -- | -- | -- | -- | -- | |
| Equity Dividend Rate (%) | -- | -- | -- | -- | -- | |
| EPS Before Extra Ordinary | ||||||
| Basic EPS | 6.80 | 5.64 | 7.85 | 7.91 | 6.50 | |
| Diluted EPS | 6.80 | 5.64 | 7.85 | 7.91 | 6.50 | |
| EPS After Extra Ordinary | ||||||
| Basic EPS. | 6.80 | 5.64 | 7.85 | 7.91 | 6.50 | |
| Diluted EPS. | 6.80 | 5.64 | 7.85 | 7.91 | 6.50 | |
| Public Share Holding | ||||||
| No Of Shares (Crores) | -- | -- | -- | -- | -- | |
| Share Holding (%) | -- | -- | -- | -- | -- | |
| Promoters and Promoter Group Shareholding | ||||||
| a) Pledged/Encumbered | ||||||
| - Number of shares (Crores) | -- | -- | -- | -- | -- | |
| - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | -- | -- | |
| - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | -- | -- | |
| b) Non-encumbered | ||||||
| - Number of shares (Crores). | -- | -- | -- | -- | -- | |
| - Per. of shares (as a % of the total sh. of prom. and promoter group). | -- | -- | -- | -- | -- | |
| - Per. of shares (as a % of the total Share Cap. of the company). | -- | -- | -- | -- | -- |
Source : Dion Global Solutions Limited
Results of Aurobindo Pharm
-
16.11.2019
Earnings hits & misses: Top 10 companies which declared Q2 numbers this week
-
13.11.2019
Aurobindo Pharm Consolidated September 2019 Net Sales at Rs 5,600.47 crore, up 17.87% Y-o-Y
-
12.11.2019
-
10.08.2019
Surprise or disappointment in Q1: Here's how top companies have performed last week
-
11.02.2019
Analysts remain positive on Aurobindo Pharma, expect stock to return 8-30% after Q3 earnings
-
25.08.2018
Pharma Q1 review: Brokerages say performance a mixed bag, but are upbeat on domestic biz
-
10.08.2017
When Rakesh Jhunjhunwala grilled Aurobindo Pharma top brass after muted Q1 results
-
24.08.2016
Aurobindo to see growth in H2; capacity constraints continue: PL
